You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
An early version of the test is being used by researchers as part of the NIH-funded Chronic Renal Insufficiency Cohort (CRIC) study.
KidneyIntelX is designed to help assess the risk of progressive decline in kidney function in patients with type 2 diabetes and chronic kidney disease.
The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.
The London-based firm hopes to also show the clinical utility of its KidneyIntelX assay for predicting the risk of the patients' progressive kidney decline.
The proceeds from the round will allow the firm to begin selling its in vitro diagnostic blood test for patients with chronic kidney disease.
The firm intends to use about $25 million to $30 million of the net proceeds for the continued development and planned commercialization of its KidneyIntelX platform.
The company said it anticipates using about $25 million to $30 million of the net proceeds for the continued development of its KidneyIntelX platform.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
Kidney disease diagnostic company RenalytixAI is planning a public offering of its American Depositary Shares and a concurrent private placement.
An analysis of 3,000 subjects found the test could identify diabetes patients at risk of developing chronic kidney disease within the next four years.